Jpmorgan Chase & CO Gemini Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.22 - $1.73 $12,534 - $17,774	-10,274 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$1.29 - $3.08 $358 - $856	-278 Reduced 2.63%	10,274 $14,000
Q4 2021 Feb 10, 2022	SELL	$2.39 - $4.0 $29,913 - $50,064	-12,516 Reduced 54.26%	10,552 $30,000
Q3 2021 Nov 12, 2021	BUY	$3.3 - $6.32 $76,124 - $145,789	23,068 New	23,068 $93,000

2.44M

Ticker GMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,244,500
Market Cap $1.05B
Description
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.